The importance of ongoing international surveillance for Creutzfeldt-Jakob disease.
Journal
Nature reviews. Neurology
ISSN: 1759-4766
Titre abrégé: Nat Rev Neurol
Pays: England
ID NLM: 101500072
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
accepted:
18
03
2021
pubmed:
12
5
2021
medline:
18
1
2022
entrez:
11
5
2021
Statut:
ppublish
Résumé
Creutzfeldt-Jakob disease (CJD) is a rapidly progressive, fatal and transmissible neurodegenerative disease associated with the accumulation of misfolded prion protein in the CNS. International CJD surveillance programmes have been active since the emergence, in the mid-1990s, of variant CJD (vCJD), a disease linked to bovine spongiform encephalopathy. Control measures have now successfully contained bovine spongiform encephalopathy and the incidence of vCJD has declined, leading to questions about the requirement for ongoing surveillance. However, several lines of evidence have raised concerns that further cases of vCJD could emerge as a result of prolonged incubation and/or secondary transmission. Emerging evidence from peripheral tissue distribution studies employing high-sensitivity assays suggests that all forms of human prion disease carry a theoretical risk of iatrogenic transmission. Finally, emerging diseases, such as chronic wasting disease and camel prion disease, pose further risks to public health. In this Review, we provide an up-to-date overview of the transmission of prion diseases in human populations and argue that CJD surveillance remains vital both from a public health perspective and to support essential research into disease pathophysiology, enhanced diagnostic tests and much-needed treatments.
Identifiants
pubmed: 33972773
doi: 10.1038/s41582-021-00488-7
pii: 10.1038/s41582-021-00488-7
pmc: PMC8109225
doi:
Substances chimiques
Prions
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
362-379Subventions
Organisme : Medical Research Council
ID : MR/J016071/1
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Références
National CJD Research & Surveillance Unit. 28th Annual Report 2019. Creutzfeldt-Jakob Disease Surveillance in the UK https://www.cjd.ed.ac.uk/sites/default/files/Report28.pdf (2020).
Uttley, L., Carroll, C., Wong, R., Hilton, D. A. & Stevenson, M. Creutzfeldt-Jakob disease: a systematic review of global incidence, prevalence, infectivity, and incubation. Lancet Infect. Dis. 20, e2–e10 (2020).
pubmed: 31876504
doi: 10.1016/S1473-3099(19)30615-2
Kovacs, G. G. et al. Genetic prion disease: the EUROCJD experience. Hum. Genet. 118, 166–174 (2005). An international study on the epidemiology of genetic prion diseases in the Euro-CJD network nations.
pubmed: 16187142
doi: 10.1007/s00439-005-0020-1
Masters, C. L. et al. Creutzfeldt-Jakob disease: patterns of worldwide occurrence and the significance of familial and sporadic clustering. Ann. Neurol. 5, 177–188 (1979).
pubmed: 371520
doi: 10.1002/ana.410050212
Brown, P. et al. Iatrogenic Creutzfeldt-Jakob disease, final assessment. Emerg. Infect. Dis. 18, 901–907 (2012). A detailed summary of the iCJD epidemic worldwide.
pubmed: 22607808
pmcid: 3358170
doi: 10.3201/eid1806.120116
Prusiner, S. B. Prions. Proc. Natl Acad. Sci. USA 95, 13363–13383 (1998).
pubmed: 9811807
pmcid: 33918
doi: 10.1073/pnas.95.23.13363
Nobel Media. The Nobel Prize in Physiology or Medicine 1997 https://www.nobelprize.org/prizes/medicine/1997/summary (2020).
Gajdusek, D. C. & Zigas, V. Kuru; clinical, pathological and epidemiological study of an acute progressive degenerative disease of the central nervous system among natives of the Eastern Highlands of New Guinea. Am. J. Med. 26, 442–469 (1959).
pubmed: 13626997
doi: 10.1016/0002-9343(59)90251-7
Collinge, J. et al. Kuru in the 21st century–an acquired human prion disease with very long incubation periods. Lancet 367, 2068–2074 (2006). A surveillance report on Kuru, a disease associated with endocannibalism in Papua New Guinea, demonstrating extensive incubation lasting several decades associated with prion protein codon 129 polymorphism status.
pubmed: 16798390
doi: 10.1016/S0140-6736(06)68930-7
National CJD Research & Surveillance Unit. Variant CJD cases worldwide https://www.cjd.ed.ac.uk/surveillance/data-and-reports (2020).
Smith, P. G. & Bradley, R. Bovine spongiform encephalopathy (BSE) and its epidemiology. Br. Med. Bull. 66, 185–198 (2003).
pubmed: 14522859
doi: 10.1093/bmb/66.1.185
World Organization for Animal Health. Number of cases of bovine spongiform encephalopathy (BSE) reported in the United Kingdom https://www.oie.int/en/animal-health-in-the-world/bse-specific-data/number-of-cases-in-the-united-kingdom/ (2020).
World Organization for Animal Health. Number of reported cases of bovine spongiform encephalopathy (BSE) in farmed cattle worldwide (excluding the United Kingdom) https://www.oie.int/animal-health-in-the-world/bse-situation-in-the-world-and-annual-incidence-rate/number-of-reported-cases-worldwide-excluding-the-united-kingdom/ (2020).
Centers for Disease Control and Prevention. Chronic Wasting Disease (CWD) https://www.cdc.gov/prions/cwd/occurrence.html (2020).
Rudge, P. et al. Iatrogenic CJD due to pituitary-derived growth hormone with genetically determined incubation times of up to 40 years. Brain 138, 3386–3399 (2015). Case series demonstrating that human growth hormone-associated iCJD can incubate for several decades, influenced by prion protein gene codon 129 polymorphism status.
pubmed: 26268531
pmcid: 4620512
doi: 10.1093/brain/awv235
Brandel, J. P. et al. Variant Creutzfeldt-Jakob disease diagnosed 7.5 years after occupational exposure. N. Engl. J. Med. 383, 83–85 (2020).
pubmed: 32609989
doi: 10.1056/NEJMc2000687
Parchi, P. et al. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann. Neurol. 46, 224–233 (1999). A large clinicopathological series on sCJD demonstrating the relationship between clinical features and the underlying genetics and neuropathology.
pubmed: 10443888
doi: 10.1002/1531-8249(199908)46:2<224::AID-ANA12>3.0.CO;2-W
Palmer, M. S., Dryden, A. J., Hughes, J. T. & Collinge, J. Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease. Nature 352, 340–342 (1991).
pubmed: 1677164
doi: 10.1038/352340a0
Collinge, J., Palmer, M. S. & Dryden, A. J. Genetic predisposition to iatrogenic Creutzfeldt-Jakob disease. Lancet 337, 1441–1442 (1991).
pubmed: 1675319
doi: 10.1016/0140-6736(91)93128-V
Mok, T. et al. Variant Creutzfeldt-Jakob disease in a patient with heterozygosity at PRNP Codon 129. N. Engl. J. Med. 376, 292–294 (2017). The first confirmed case of vCJD with prion protein gene codon 129 heterozygosity, a factor associated with prolonged incubation in other forms of acquired prion disease.
pubmed: 28099827
doi: 10.1056/NEJMc1610003
Chen, C. & Dong, X. P. Epidemiological characteristics of human prion diseases. Infect. Dis. Poverty 5, 47 (2016).
pubmed: 27251305
pmcid: 4890484
doi: 10.1186/s40249-016-0143-8
Parchi, P. et al. Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann. Neurol. 39, 767–778 (1996).
pubmed: 8651649
doi: 10.1002/ana.410390613
Head, M. W. et al. Prion protein heterogeneity in sporadic but not variant Creutzfeldt-Jakob disease: UK cases 1991-2002. Ann. Neurol. 55, 851–859 (2004).
pubmed: 15174020
doi: 10.1002/ana.20127
Tee, B. L., Longoria Ibarrola, E. M. & Geschwind, M. D. Prion diseases. Neurol. Clin. 36, 865–897 (2018).
pubmed: 30366560
doi: 10.1016/j.ncl.2018.07.005
Will, R. G. et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 347, 921–925 (1996). The original case series demonstrating a new variant of CJD in the UK with atypical features, identifying the beginning of the vCJD epidemic.
pubmed: 8598754
doi: 10.1016/S0140-6736(96)91412-9
Chazot, G. et al. New variant of Creutzfeldt-Jakob disease in a 26-year-old French man. Lancet 347, 1181 (1996). The first identified case of vCJD in France, following the recognition of vCJD in the UK the same year.
pubmed: 8609775
doi: 10.1016/S0140-6736(96)90638-8
Maheshwari, A. et al. Recent US case of variant Creutzfeldt-Jakob disease — global implications. Emerg. Infect. Dis. 21, 750–759 (2015).
pubmed: 25897712
pmcid: 4412247
doi: 10.3201/eid2105.142017
European Centre for Disease Prevention and Control. Creutzfeldt-Jakob disease. Annual Epidemiological Report for 2017. (ECDC, 2020).
Brandel, J. P., Peckeu, L. & Haïk, S. The French surveillance network of Creutzfeldt-Jakob disease. Epidemiological data in France and worldwide. Transfus. Clin. Biol. 20, 395–397 (2013).
pubmed: 23587616
doi: 10.1016/j.tracli.2013.02.029
Heinemann, U. et al. Creutzfeldt-Jakob disease in Germany: a prospective 12-year surveillance. Brain 130, 1350–1359 (2007).
pubmed: 17472986
doi: 10.1093/brain/awm063
Maddox, R. A. et al. Prion disease incidence in the United States: 2003-2015. Neurology 94, e153–e157 (2020).
pubmed: 31757870
doi: 10.1212/WNL.0000000000008680
Geschwind, M. D. Prion diseases. Continuum 21, 1612–1638 (2015).
pubmed: 26633779
Ladogana, A. et al. Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada. Neurology 64, 1586–1591 (2005).
pubmed: 15883321
doi: 10.1212/01.WNL.0000160117.56690.B2
Horan, G. et al. Creutzfeldt-Jakob disease in Ireland: epidemiological aspects 1980-2002. Eur. Neurol. 51, 132–137 (2004).
pubmed: 14988606
doi: 10.1159/000077063
Velásquez-Pérez, L., Rembao-Bojorquez, D., Guevara, J., Guadarrama-Torres, R. M. & Trejo-Contreras, A. Creutzfeldt-Jakob disease in Mexico. Neuropathology 27, 419–428 (2007).
pubmed: 18018474
doi: 10.1111/j.1440-1789.2007.00807.x
Begue, C. et al. Creutzfeldt-Jakob disease surveillance in Argentina, 1997-2008. Neuroepidemiology 37, 193–202 (2011).
pubmed: 22067221
doi: 10.1159/000331907
Martins, V. R., Gomes, H. R., Chimelli, L., Rosemberg, S. & Landemberger, M. C. Prion diseases are undercompulsory notification in Brazil: surveillance of cases evaluated by biochemicaland/or genetic markers from 2005 to 2007. Dement. Neuropsychol. 1, 347–355 (2007).
pubmed: 29213410
pmcid: 5619428
doi: 10.1590/S1980-57642008DN10400004
Adam, A. M. & Akuku, O. Creutzfeldt-Jakob disease in Kenya. Trop. Med. Int. Health 10, 710–712 (2005).
pubmed: 15960711
doi: 10.1111/j.1365-3156.2005.01435.x
Hajjaj, I. & Kissani, N. First case of presumed sporadic Creutzfeldt-Jakob disease in Marrakech, Morocco [In French]. Med. Trop. 71, 289–291 (2011).
Negm, M. & Hashish, E. Probable Creutzfeldt-Jakob disease — a case report at Suez Canal University Hospital, Egypt. Egypt. J. Neurol. Psychiatry Neurosurg. 55, 36 (2019).
doi: 10.1186/s41983-019-0085-8
Nozaki, I. et al. Prospective 10-year surveillance of human prion diseases in Japan. Brain 133, 3043–3057 (2010).
pubmed: 20855418
doi: 10.1093/brain/awq216
Shi, Q. et al. Analysis of the advantage features of Beijing surveillance network for Creutzfeldt-Jakob disease. Prion 9, 304–314 (2015).
pubmed: 26251963
pmcid: 4601330
doi: 10.1080/19336896.2015.1075115
Lolekha, P., Rasheed, A. & Yotsarawat, C. Creutzfeldt-Jakob disease in a tertiary care hospital in Thailand: a case series and review of the literature. J. Mov. Disord. 8, 136–140 (2015).
pubmed: 26413241
pmcid: 4572664
doi: 10.14802/jmd.15014
Qi, C., Zhang, J. T., Zhao, W., Xing, X. W. & Yu, S. Y. Sporadic Creutzfeldt-Jakob disease: a retrospective analysis of 104 cases. Eur. Neurol. 83, 65–72 (2020).
pubmed: 32344417
doi: 10.1159/000507189
Lim, J. S. et al. Characteristics of Korean patients with suspected Creutzfeldt-Jakob disease with 14-3-3 protein in cerebrospinal fluid: Preliminary study of the Korean Creutzfeldt-Jakob disease active surveillance program. Prion 9, 136–143 (2015).
pubmed: 25996401
pmcid: 4601202
doi: 10.1080/19336896.2015.1022020
Klug, G. M. et al. Intensity of human prion disease surveillance predicts observed disease incidence. J. Neurol. Neurosurg. Psychiatry 84, 1372–1377 (2013).
pubmed: 23965290
doi: 10.1136/jnnp-2012-304820
Stehmann, C. et al. Creutzfeldt-Jakob disease surveillance in Australia: update to 31 December 2019. Commun. Dis. Intell. https://doi.org/10.33321/cdi.2019.43.35 (2020).
doi: 10.33321/cdi.2019.43.35
Ahmad, A., Rao, F. & Aieshah, S. Two cases of Creutzfeldt-Jakob disease from an ongoing dementia registry in Pakistan. J. Pak. Med. Assoc. 64, 705–707 (2014).
pubmed: 25252497
Kharel, H., Adhikari, P., Pokhrel, N. B., Kharel, Z. & Nepal, G. The first reported case of Creutzfeldt-Jakob disease from Nepal. Clin. Case Rep. 8, 198–202 (2020).
pubmed: 31998516
doi: 10.1002/ccr3.2609
Safar, J. G. Molecular pathogenesis of sporadic prion diseases in man. Prion 6, 108–115 (2012).
pubmed: 22421210
pmcid: 3366352
doi: 10.4161/pri.18666
Collins, S. et al. Surgical treatment and risk of sporadic Creutzfeldt-Jakob disease: a case-control study. Lancet 353, 693–697 (1999).
pubmed: 10073510
doi: 10.1016/S0140-6736(98)08138-0
Mahillo-Fernandez, I. et al. Surgery and risk of sporadic Creutzfeldt-Jakob disease in Denmark and Sweden: registry-based case-control studies. Neuroepidemiology 31, 229–240 (2008).
pubmed: 18843192
pmcid: 2790765
doi: 10.1159/000163097
Puopolo, M., Ladogana, A., Vetrugno, V. & Pocchiari, M. Transmission of sporadic Creutzfeldt-Jakob disease by blood transfusion: risk factor or possible biases. Transfusion 51, 1556–1566 (2011).
pubmed: 21214582
doi: 10.1111/j.1537-2995.2010.03004.x
de Pedro Cuesta, J. et al. Sensitivity to biases of case-control studies on medical procedures, particularly surgery and blood transfusion, and risk of Creutzfeldt-Jakob disease. Neuroepidemiology 39, 1–18 (2012). A review article evaluating 18 case–control studies in sCJD demonstrating the methodological challenges involved in working with CJD.
pubmed: 22777385
doi: 10.1159/000339318
Alperovitch, A. et al. Codon 129 prion protein genotype and sporadic Creutzfeldt-Jakob disease. Lancet 353, 1673–1674 (1999).
pubmed: 10335789
doi: 10.1016/S0140-6736(99)01342-2
Cooper, S. A., Murray, K. L., Heath, C. A., Will, R. G. & Knight, R. S. Isolated visual symptoms at onset in sporadic Creutzfeldt-Jakob disease: the clinical phenotype of the “Heidenhain variant”. Br. J. Ophthalmol. 89, 1341–1342 (2005).
pubmed: 16170128
pmcid: 1772891
doi: 10.1136/bjo.2005.074856
Hermann, P. et al. Validation and utilization of amended diagnostic criteria in Creutzfeldt-Jakob disease surveillance. Neurology 91, e331–e338 (2018). Prospective study validating the 2017 diagnostic criteria for sCJD demonstrating a sensitivity of 97% and a specificity of 99%.
pubmed: 29934424
doi: 10.1212/WNL.0000000000005860
Zerr, I. et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain 132, 2659–2668 (2009). International study demonstrating the utility of MRI for the diagnosis of sCJD.
pubmed: 19773352
pmcid: 2759336
doi: 10.1093/brain/awp191
Tschampa, H. J. et al. Pattern of cortical changes in sporadic Creutzfeldt-Jakob disease. Am. J. Neuroradiol. 28, 1114–1118 (2007).
pubmed: 17569970
pmcid: 8134134
doi: 10.3174/ajnr.A0496
Steinhoff, B. J. et al. Diagnostic value of periodic complexes in Creutzfeldt-Jakob disease. Ann. Neurol. 56, 702–708 (2004).
pubmed: 15449324
doi: 10.1002/ana.20261
Schmitz, M. et al. Validation of 14-3-3 protein as a marker in sporadic Creutzfeldt-Jakob disease diagnostic. Mol. Neurobiol. 53, 2189–2199 (2016).
pubmed: 25947081
doi: 10.1007/s12035-015-9167-5
Chohan, G. et al. The role of cerebrospinal fluid 14-3-3 and other proteins in the diagnosis of sporadic Creutzfeldt-Jakob disease in the UK: a 10-year review. J. Neurol. Neurosurg. Psychiatry 81, 1243–1248 (2010).
pubmed: 20855493
doi: 10.1136/jnnp.2009.197962
Sanchez-Juan, P. et al. CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 67, 637–643 (2006).
pubmed: 16924018
doi: 10.1212/01.wnl.0000230159.67128.00
Green, A. J. E. RT-QuIC: a new test for sporadic CJD. Pract. Neurol. 19, 49–55 (2019).
pubmed: 30282760
doi: 10.1136/practneurol-2018-001935
Cramm, M. et al. Stability and reproducibility underscore utility of RT-QuIC for diagnosis of Creutzfeldt-Jakob disease. Mol. Neurobiol. 53, 1896–1904 (2016). International study demonstrating consistently high sensitivity of RT-QuIC and specificity of 99% for the diagnosis of CJD.
pubmed: 25823511
doi: 10.1007/s12035-015-9133-2
Atarashi, R., Sano, K., Satoh, K. & Nishida, N. Real-time quaking-induced conversion: a highly sensitive assay for prion detection. Prion 5, 150–153 (2011).
pubmed: 21778820
pmcid: 3226039
doi: 10.4161/pri.5.3.16893
Ironside, J. W., Ritchie, D. L. & Head, M. W. Phenotypic variability in human prion diseases. Neuropathol. Appl. Neurobiol. 31, 565–579 (2005).
pubmed: 16281905
doi: 10.1111/j.1365-2990.2005.00697.x
Wadsworth, J. D. & Collinge, J. Molecular pathology of human prion disease. Acta Neuropathol. 121, 69–77 (2011).
pubmed: 20694796
doi: 10.1007/s00401-010-0735-5
Mead, S., Lloyd, S. & Collinge, J. Genetic factors in mammalian prion diseases. Annu. Rev. Genet. 53, 117–147 (2019).
pubmed: 31537104
doi: 10.1146/annurev-genet-120213-092352
Mead, S. Prion disease genetics. Eur. J. Hum. Genet. 14, 273–281 (2006).
pubmed: 16391566
doi: 10.1038/sj.ejhg.5201544
Public Health England. Public health action following a report of a new case of CJD or a person at increased risk of CJD. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/474338/CJD_public_health_action_new_case_301015.pdf (2015).
US Department of Health and Human Services, Food and Drug Administration. Recommendations to reduce the possible risk of transmission of Creutzfeldt-Jakob disease and variant Creutzfeldt-Jakob disease by blood and blood components. https://www.fda.gov/media/124156/download (2020).
Mastrianni, J. A. The genetics of prion diseases. Genet. Med. 12, 187–195 (2010).
pubmed: 20216075
doi: 10.1097/GIM.0b013e3181cd7374
Bagyinszky, E. et al. Early-onset Alzheimer’s disease patient with prion (PRNP) p.Val180Ile mutation. Neuropsychiatr. Dis. Treat. 15, 2003–2013 (2019).
pubmed: 31410005
pmcid: 6645694
doi: 10.2147/NDT.S215277
Moore, R. C. et al. Huntington disease phenocopy is a familial prion disease. Am. J. Hum. Genet. 69, 1385–1388 (2001).
pubmed: 11593450
pmcid: 1235549
doi: 10.1086/324414
Webb, T. E. et al. Phenotypic heterogeneity and genetic modification of P102L inherited prion disease in an international series. Brain 131, 2632–2646 (2008).
pubmed: 18757886
pmcid: 2570713
doi: 10.1093/brain/awn202
Paucar, M. et al. Genotype-phenotype analysis in inherited prion disease with eight octapeptide repeat insertional mutation. Prion 7, 501–510 (2013).
pubmed: 24275071
pmcid: 4201619
doi: 10.4161/pri.27260
Oldoni, E. et al. PRNP P39L variant is a rare cause of frontotemporal dementia in Italian population. J. Alzheimers Dis. 50, 353–357 (2016).
pubmed: 26757195
doi: 10.3233/JAD-150863
Nitrini, R. et al. Prion disease resembling frontotemporal dementia and parkinsonism linked to chromosome 17. Arq. Neuropsiquiatr. 59, 161–164 (2001).
pubmed: 11400017
doi: 10.1590/S0004-282X2001000200001
Cracco, L., Appleby, B. S. & Gambetti, P. Fatal familial insomnia and sporadic fatal insomnia. Handb. Clin. Neurol. 153, 271–299 (2018).
pubmed: 29887141
doi: 10.1016/B978-0-444-63945-5.00015-5
Goldfarb, L. G. et al. Fatal familial insomnia and familial Creutzfeldt-Jakob disease: disease phenotype determined by a DNA polymorphism. Science 258, 806–808 (1992).
pubmed: 1439789
doi: 10.1126/science.1439789
Takada, L. T. et al. Genetic prion disease: experience of a rapidly progressive dementia center in the United States and a review of the literature. Am. J. Med. Genet. B Neuropsychiatr. Genet. 174, 36–69 (2017).
pubmed: 27943639
pmcid: 7207989
doi: 10.1002/ajmg.b.32505
Shi, Q. et al. The features of genetic prion diseases based on Chinese surveillance program. PLoS One 10, e0139552 (2015).
pubmed: 26488179
pmcid: 4619501
doi: 10.1371/journal.pone.0139552
Hsiao, K. et al. Mutation of the prion protein in Libyan Jews with Creutzfeldt-Jakob disease. N. Engl. J. Med. 324, 1091–1097 (1991).
pubmed: 2008182
doi: 10.1056/NEJM199104183241604
Ladogana, A. et al. High incidence of genetic human transmissible spongiform encephalopathies in Italy. Neurology 64, 1592–1597 (2005).
pubmed: 15883322
doi: 10.1212/01.WNL.0000160118.26865.11
Montagna, P., Gambetti, P., Cortelli, P. & Lugaresi, E. Familial and sporadic fatal insomnia. Lancet Neurol. 2, 167–176 (2003).
pubmed: 12849238
doi: 10.1016/S1474-4422(03)00323-5
Jeong, B. H. & Kim, Y. S. Genetic studies in human prion diseases. J. Korean Med. Sci. 29, 623–632 (2014).
pubmed: 24851016
pmcid: 4024956
doi: 10.3346/jkms.2014.29.5.623
Melis, M. et al. Genetic Creutzfeldt-Jakob disease in Sardinia: a case series linked to the PRNP R208H mutation due to a single founder effect. Neurogenetics 21, 251–257 (2020).
pubmed: 32458274
doi: 10.1007/s10048-020-00618-1
Beck, J., Collinge, J. & Mead, S. Prion protein gene M232R variation is probably an uncommon polymorphism rather than a pathogenic mutation. Brain 135, e209 (2012).
pubmed: 22108575
doi: 10.1093/brain/awr294
Rodriguez, M. M. et al. A novel mutation (G114V) in the prion protein gene in a family with inherited prion disease. Neurology 64, 1455–1457 (2005).
pubmed: 15851745
doi: 10.1212/01.WNL.0000158618.39527.93
Katrak, S. M. et al. Familial Creutzfeldt-Jakob disease in an Indian kindred. Ann. Indian. Acad. Neurol. 22, 458–461 (2019).
pubmed: 31736569
pmcid: 6839320
Will, R. G. Acquired prion disease: iatrogenic CJD, variant CJD, kuru. Br. Med. Bull. 66, 255–265 (2003).
pubmed: 14522863
doi: 10.1093/bmb/66.1.255
Collinge, J. et al. A clinical study of kuru patients with long incubation periods at the end of the epidemic in Papua New Guinea. Philos. Trans. R. Soc. Lond. B Biol. Sci. 363, 3725–3739 (2008).
pubmed: 18849289
pmcid: 2581654
doi: 10.1098/rstb.2008.0068
Alpers, M. P. Review. The epidemiology of kuru: monitoring the epidemic from its peak to its end. Philos. Trans. R. Soc. Lond. B Biol. Sci. 363, 3707–3713 (2008).
pubmed: 18849286
pmcid: 2577135
doi: 10.1098/rstb.2008.0071
Duffy, P. et al. Letter: Possible person-to-person transmission of Creutzfeldt-Jakob disease. N. Engl. J. Med. 290, 692–693 (1974).
pubmed: 4591849
doi: 10.1056/NEJM197403212901220
Koch, T. K., Berg, B. O., De Armond, S. J. & Gravina, R. F. Creutzfeldt-Jakob disease in a young adult with idiopathic hypopituitarism. Possible relation to the administration of cadaveric human growth hormone. N. Engl. J. Med. 313, 731–733 (1985).
pubmed: 3897861
doi: 10.1056/NEJM198509193131206
Boyd, A. et al. Transmissible spongiform encephalopathies in Australia. Commun. Dis. Intell. Q. Rep. 25, 248–252 (2001).
pubmed: 11806657
Croes, E. A., Roks, G., Jansen, G. H., Nijssen, P. C. & van Duijn, C. M. Creutzfeldt-Jakob disease 38 years after diagnostic use of human growth hormone. J. Neurol. Neurosurg. Psychiatry 72, 792–793 (2002).
pubmed: 12023427
pmcid: 1737920
doi: 10.1136/jnnp.72.6.792
Brown, P., Brandel, J.-P., Preese, M. & Sato, T. Iatrogenic Creutzfeldt–Jakob disease: the waning of an era. Neurology 67, 389–393 (2006).
pubmed: 16855204
doi: 10.1212/01.wnl.0000231528.65069.3f
Ae, R. et al. Update: dura mater graft-associated Creutzfeldt-Jakob disease - Japan, 1975-2017. MMWR Morb. Mortal Wkly Rep. 67, 274–278 (2018). Most recently published report on dura mater graft-associated iCJD in Japan, the centre of the global epidemic.
pubmed: 29518068
pmcid: 5844283
doi: 10.15585/mmwr.mm6709a3
US Department of Health and Human Services, Food and Drug Administration. Guidance for Industry and FDA Staff. Class II Special Controls Guidance Document: Human Dura Mater https://www.fda.gov/media/71309/download (2003).
World Health Organization. WHO Infection Control Guidelines for Transmissible Spongiform Encephalopathies. Report of a WHO consultation Geneva, Switzerland, 23-26 March 1999. (WHO, 1999).
Cali, I. et al. Distinct pathological phenotypes of Creutzfeldt-Jakob disease in recipients of prion-contaminated growth hormone. Acta Neuropathol. Commun. 3, 37 (2015).
pubmed: 26108478
pmcid: 4479081
doi: 10.1186/s40478-015-0214-2
Hamaguchi, T. et al. Insight into the frequent occurrence of dura mater graft-associated Creutzfeldt-Jakob disease in Japan. J. Neurol. Neurosurg. Psychiatry 84, 1171–1175 (2013).
pubmed: 23595947
doi: 10.1136/jnnp-2012-304850
Abrams, J. Y. et al. Lower risk of Creutzfeldt-Jakob disease in pituitary growth hormone recipients initiating treatment after 1977. J. Clin. Endocrinol. Metab. 96, E1666–E1669 (2011).
pubmed: 21816775
doi: 10.1210/jc.2011-1357
Brandel, J. P. et al. Distribution of codon 129 genotype in human growth hormone-treated CJD patients in France and the UK. Lancet 362, 128–130 (2003).
pubmed: 12867116
doi: 10.1016/S0140-6736(03)13867-6
Zeidler, M. et al. New variant Creutzfeldt-Jakob disease: neurological features and diagnostic tests. Lancet 350, 903–907 (1997).
pubmed: 9314867
doi: 10.1016/S0140-6736(97)07472-2
National CJD Research & Surveillance Unit. Creutzfeldt-Jakob Disease Surveillance in the UK. 27th Annual Report 2018. http://www.cjd.ed.ac.uk/sites/default/files/report27.pdf (2019).
Spencer, M. D., Knight, R. S. & Will, R. G. First hundred cases of variant Creutzfeldt-Jakob disease: retrospective case note review of early psychiatric and neurological features. BMJ 324, 1479–1482 (2002). Cohort study of 100 individuals with vCJD describing the clinical features important for diagnosis and surveillance.
pubmed: 12077031
pmcid: 116442
doi: 10.1136/bmj.324.7352.1479
Heath, C. A. et al. Validation of diagnostic criteria for variant Creutzfeldt-Jakob disease. Ann. Neurol. 67, 761–770 (2010).
pubmed: 20517937
Collie, D. A. et al. Diagnosing variant Creutzfeldt-Jakob disease with the pulvinar sign: MR imaging findings in 86 neuropathologically confirmed cases. Am. J. Neuroradiol. 24, 1560–1569 (2003). Large study characterizing the pulvinar thalamic abnormalities seen on MRI in vCJD.
pubmed: 13679271
pmcid: 7973975
Green, A. J. E. et al. Use of 14–3–3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt-Jakob disease. J. Neurol. Neurosurg. Psychiatry 70, 744 (2001).
pubmed: 11385008
pmcid: 1737395
doi: 10.1136/jnnp.70.6.744
Ironside, J. W. Neuropathology of variant Creutzfeldt-Jakob disease. C. R. Biol. 325, 27–31 (2002).
pubmed: 11862618
doi: 10.1016/S1631-0691(02)01381-1
Ward, H. J. et al. Risk factors for variant Creutzfeldt-Jakob disease: a case-control study. Ann. Neurol. 59, 111–120 (2006).
pubmed: 16287153
doi: 10.1002/ana.20708
Ironside, J. W. Variant Creutzfeldt-Jakob disease. Haemophilia 16, 175–180 (2010).
pubmed: 20590878
doi: 10.1111/j.1365-2516.2010.02317.x
Brown, P. Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease. BMJ 322, 841–844 (2001).
pubmed: 11290640
pmcid: 1120011
doi: 10.1136/bmj.322.7290.841
Food Standards Agency. Bovine Spongiform Encephalopathy. Food Standards Agency https://www.food.gov.uk/safety-hygiene/bovine-spongiform-encephalopathy-bse (2017).
World Organization for Animal Health. Bovine Spongiform Encephalopathy (BSE) https://www.oie.int/en/animal-health-in-the-world/animal-diseases/Bovine-spongiform-encephalopathy/ (2018).
Centers for Disease Control and Prevention. Bovine Spongiform Encephalopathy (BSE), or Mad Cow Disease. Control Measures https://www.cdc.gov/prions/bse/control-measures.html (2018).
The European Parliament. Regulation (EC) no 999/2001 of the European Parliament and of the Council as of 22 May 2001 laying down rules for the prevention, control and eradication of certain transmissible spongiform encephalopathies. Official Journal of the European Communities L147/1-40. https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX:32001R0999&from=EN (2001).
BBC News. Timeline: British Beef Ban http://news.bbc.co.uk/2/hi/uk_news/4785610.stm#:~:text=MARCH%201996,live%20cattle%2C%20meat%20and%20products (2006).
Bradley, R. & Wilesmith, J. W. Epidemiology and control of bovine spongiform encephalopathy (BSE). Br. Med. Bull. 49, 932–959 (1993).
pubmed: 8137136
doi: 10.1093/oxfordjournals.bmb.a072654
Collinge, J., Sidle, K. C., Meads, J., Ironside, J. & Hill, A. F. Molecular analysis of prion strain variation and the aetiology of ‘new variant’ CJD. Nature 383, 685–690 (1996). Landmark study demonstrating molecular characteristics and transmission properties of vCJD-associated prion protein with similarity to that seen in BSE, suggesting BSE was the source of vCJD.
pubmed: 8878476
doi: 10.1038/383685a0
Palmer Clephan, M. A week that shook the meat industry: the effects on the UK beef industry of the BSE crisis. Br. Food J. 98, 17–25 (1996).
doi: 10.1108/00070709610153650
Food Standards Agency. BSE and Beef. New Controls Explained. Advicsory Committee for Social Science https://acss.food.gov.uk/sites/default/files/multimedia/pdfs/publication/bsebooklet.pdf (2006).
BBC News. UK Beef Export Ban Lifted by EU http://news.bbc.co.uk/1/hi/uk/4784810.stm (2006).
European Commission. BSE: UK Embargo to be Lifted https://ec.europa.eu/commission/presscorner/detail/en/IP_06_278 (2006).
BBC News. UK Beef Exports to US Resume after more than 20 years https://www.bbc.co.uk/news/business-54347426 (2020).
Fickling, D. EU Lifts Ban on British Beef Exports https://www.theguardian.com/uk/2006/may/03/bse.eu (2006).
BBC News. ‘Mad cow disease’: What is BSE? https://www.bbc.co.uk/news/uk-45906585 (2018).
Cooper, J. D. & Bird, S. M. UK bovine carcass meat consumed as burgers, sausages and other meat products: by birth cohort and gender. J. Cancer Epidemiol. Prev. 7, 49–57 (2002).
pubmed: 12501955
doi: 10.1080/147666502321082719
Cooper, J. D. & Bird, S. M. UK dietary exposure to BSE in beef mechanically recovered meat: by birth cohort and gender. J. Cancer Epidemiol. Prev. 7, 59–70 (2002).
pubmed: 12501956
doi: 10.1080/147666502321082728
Cooper, J. D. & Bird, S. M. UK dietary exposure to BSE in head meat: by birth cohort and gender. J. Cancer Epidemiol. Prev. 7, 71–83 (2002).
pubmed: 12501957
doi: 10.1080/147666502321082737
Chen, C.-C. & Wang, Y.-H. Estimation of the exposure of the UK population to the bovine spongiform encephalopathy agent through dietary intake during the period 1980 to 1996. PLoS One 9, e94020 (2014).
pubmed: 24736322
pmcid: 3988046
doi: 10.1371/journal.pone.0094020
Chadeau-Hyam, M. et al. Estimation of the exposure of the French population to the BSE agent: comparison of the 1980-95 consumption of beef products containing mechanically recovered meat in France and the UK, by birth cohort and gender. Stat. Methods Med. Res. 12, 247–260 (2003).
pubmed: 12828245
doi: 10.1191/0962280203sm330ra
Reuters. France confirms case of mad cow disease Reuters https://www.reuters.com/article/us-france-madcow-idUSKCN0WQ15S (2016).
BBC News. ‘Mad cow disease’ at Aberdeenshire farm after BSE confirmed https://www.bbc.co.uk/news/uk-scotland-north-east-orkney-shetland-45901043 (2018).
Bruce, M. E. et al. Transmissions to mice indicate that ‘new variant’ CJD is caused by the BSE agent. Nature 389, 498–501 (1997).
pubmed: 9333239
doi: 10.1038/39057
Lasmezas, C. I. et al. BSE transmission to macaques. Nature 381, 743–744 (1996).
pubmed: 8657276
doi: 10.1038/381743a0
Collinge, J. et al. Unaltered susceptibility to BSE in transgenic mice expressing human prion protein. Nature 378, 779–783 (1995).
pubmed: 8524411
doi: 10.1038/378779a0
Will, R. G., Matthews, W. B., Smith, P. G. & Hudson, C. A retrospective study of Creutzfeldt-Jakob disease in England and Wales 1970-1979. II: Epidemiology. J. Neurol. Neurosurg. Psychiatry 49, 749–755 (1986).
pubmed: 3528394
pmcid: 1028897
doi: 10.1136/jnnp.49.7.749
Will, R. G. et al. Descriptive epidemiology of Creutzfeldt-Jakob disease in six European countries, 1993–1995. Ann. Neurol. 43, 763–767 (1998).
pubmed: 9629846
doi: 10.1002/ana.410430611
Puopolo, M. et al. Mortality trend from sporadic Creutzfeldt-Jakob disease (CJD) in Italy, 1993-2000. J. Clin. Epidemiol. 56, 494–499 (2003).
pubmed: 12812825
doi: 10.1016/S0895-4356(02)00606-6
Nakamura, Y. et al. Incidence rate of Creutzfeldt-Jakob disease in Japan. Int. J. Epidemiol. 28, 130–134 (1999).
pubmed: 10195677
doi: 10.1093/ije/28.1.130
Case Western Reserve University. National Prion Disease Pathology Surveillance Center https://case.edu/medicine/pathology/divisions/prion-center (2021).
Brandel, J. P. et al. Variant Creutzfeldt-Jakob disease in France and the United Kingdom: evidence for the same agent strain. Ann. Neurol. 65, 249–256 (2009).
pubmed: 19334063
doi: 10.1002/ana.21583
Riverol, M. et al. Variant Creutzfeldt-Jakob disease occurring in mother and son. J. Neurol. Neurosurg. Psychiatry 83, 235–236 (2012).
pubmed: 21257982
doi: 10.1136/jnnp.2010.232074
Coulthart, M. B. et al. A case cluster of variant Creutzfeldt-Jakob disease linked to the Kingdom of Saudi Arabia. Brain 139, 2609–2616 (2016).
pubmed: 27671029
pmcid: 5082737
doi: 10.1093/brain/aww206
Kaski, D. et al. Variant CJD in an individual heterozygous for PRNP codon 129. Lancet 374, 2128 (2009).
pubmed: 20109837
doi: 10.1016/S0140-6736(09)61568-3
Wells, G. A. et al. A novel progressive spongiform encephalopathy in cattle. Vet. Rec. 121, 419–420 (1987).
pubmed: 3424605
doi: 10.1136/vr.121.18.419
Appleby, B. S. et al. Characteristics of established and proposed sporadic Creutzfeldt-Jakob disease variants. Arch. Neurol. 66, 208–215 (2009).
pubmed: 19204157
Hamaguchi, T. et al. Clinical diagnosis of MM2-type sporadic Creutzfeldt-Jakob disease. Neurology 64, 643–648 (2005).
pubmed: 15728285
doi: 10.1212/01.WNL.0000151847.57956.FA
Krasnianski, A. et al. Clinical findings and diagnostic tests in the MV2 subtype of sporadic CJD. Brain 129, 2288–2296 (2006).
pubmed: 16720682
doi: 10.1093/brain/awl123
Meissner, B. et al. Sporadic Creutzfeldt-Jakob disease: clinical and diagnostic characteristics of the rare VV1 type. Neurology 65, 1544–1550 (2005).
pubmed: 16221949
doi: 10.1212/01.wnl.0000184674.32924.c9
National CJD Research and Surveillance Unit. Estimation of the incidence of variant Creutzfeldt-Jakob disease diagnoses and deaths in the UK January 1994-December 2011 https://www.cjd.ed.ac.uk/sites/default/files/cjdq72.pdf (2012).
Klitzman, R. L. Incubation period of human prion disease. Lancet 368, 913 (2006).
pubmed: 16962870
doi: 10.1016/S0140-6736(06)69360-4
Moore, R. A., Vorberg, I. & Priola, S. A. Species barriers in prion diseases–brief review. Arch. Virol. Suppl. 19, 187–202 (2005).
Hagiwara, K. I., Hara, H. & Hanada, K. Species-barrier phenomenon in prion transmissibility from a viewpoint of protein science. J. Biochem. 153, 139–145 (2013).
pubmed: 23284000
doi: 10.1093/jb/mvs148
Hewitt, P. E., Llewelyn, C. A., Mackenzie, J. & Will, R. G. Creutzfeldt-Jakob disease and blood transfusion: results of the UK transfusion medicine epidemiological review study. Vox Sang. 91, 221–230 (2006). UK surveillance study demonstrating two cases of transfusion-transmitted vCJD and another case of pre-clinical vCJD.
pubmed: 16958834
doi: 10.1111/j.1423-0410.2006.00833.x
Urwin, P. J., Mackenzie, J. M., Llewelyn, C. A., Will, R. G. & Hewitt, P. E. Creutzfeldt-Jakob disease and blood transfusion: updated results of the UK Transfusion Medicine Epidemiology Review Study. Vox Sang. 110, 310–316 (2016).
pubmed: 26709606
doi: 10.1111/vox.12371
Wadsworth, J. D. et al. Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay. Lancet 358, 171–180 (2001). Autopsy study demonstrating peripheral presence of prion protein in the lymphoreticular system of individuals with vCJD.
pubmed: 11476832
doi: 10.1016/S0140-6736(01)05403-4
Hilton, D. A. et al. Specificity of lymphoreticular accumulation of prion protein for variant Creutzfeldt-Jakob disease. J. Clin. Pathol. 57, 300–302 (2004).
pubmed: 14990604
pmcid: 1770247
doi: 10.1136/jcp.2003.012278
Notari, S. et al. Multiorgan detection and characterization of protease-resistant prion protein in a case of variant CJD examined in the United States. PLoS One 5, e8765 (2010).
pubmed: 20098730
pmcid: 2808239
doi: 10.1371/journal.pone.0008765
Hilton, D. A. Pathogenesis and prevalence of variant Creutzfeldt-Jakob disease. J. Pathol. 208, 134–141 (2006).
pubmed: 16362983
doi: 10.1002/path.1880
Hilton, D. A. et al. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. J. Pathol. 203, 733–739 (2004). The first in a trilogy of studies demonstrating prevalent abnormal prion protein in resected appendix tissues derived from UK individuals exposed to BSE.
pubmed: 15221931
doi: 10.1002/path.1580
Gill, O. N. et al. Prevalent abnormal prion protein in human appendixes after bovine spongiform encephalopathy epizootic: large scale survey. BMJ 347, f5675 (2013). The second in a trilogy of studies demonstrating prevalent abnormal prion protein in resected appendix tissues derived from UK individuals exposed to BSE.
pubmed: 24129059
pmcid: 3805509
doi: 10.1136/bmj.f5675
Gill, O. N. et al. Prevalence in Britain of abnormal prion protein in human appendices before and after exposure to the cattle BSE epizootic. Acta Neuropathol. 139, 965–976 (2020). The third in a trilogy of studies, demonstrating abnormal prion protein in appendices resected from UK individuals outside of the established window of exposure to BSE.
pubmed: 32232565
pmcid: 7244468
doi: 10.1007/s00401-020-02153-7
Clewley, J. P. et al. Prevalence of disease related prion protein in anonymous tonsil specimens in Britain: cross sectional opportunistic survey. BMJ 338, b1442 (2009).
pubmed: 19460798
pmcid: 2685439
doi: 10.1136/bmj.b1442
Hill, A. F. et al. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet 353, 183–189 (1999).
pubmed: 9923873
doi: 10.1016/S0140-6736(98)12075-5
Wroe, S. J. et al. Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet 368, 2061–2067 (2006).
pubmed: 17161728
doi: 10.1016/S0140-6736(06)69835-8
Llewelyn, C. A. et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 363, 417–421 (2004).
pubmed: 14962520
doi: 10.1016/S0140-6736(04)15486-X
Peden, A. H., Head, M. W., Ritchie, D. L., Bell, J. E. & Ironside, J. W. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 364, 527–529 (2004).
pubmed: 15302196
doi: 10.1016/S0140-6736(04)16811-6
Davidson, L. R., Llewelyn, C. A., Mackenzie, J. M., Hewitt, P. E. & Will, R. G. Variant CJD and blood transfusion: are there additional cases? Vox Sang. 107, 220–225 (2014).
pubmed: 24916465
doi: 10.1111/vox.12161
Peden, A. et al. Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia 16, 296–304 (2010).
pubmed: 20070383
doi: 10.1111/j.1365-2516.2009.02181.x
Houston, F., Foster, J. D., Chong, A., Hunter, N. & Bostock, C. J. Transmission of BSE by blood transfusion in sheep. Lancet 356, 999–1000 (2000).
pubmed: 11041403
doi: 10.1016/S0140-6736(00)02719-7
McCutcheon, S. et al. All clinically-relevant blood components transmit prion disease following a single blood transfusion: a sheep model of vCJD. PLoS One 6, e23169 (2011).
pubmed: 21858015
pmcid: 3157369
doi: 10.1371/journal.pone.0023169
Bishop, M. T. et al. Prion infectivity in the spleen of a PRNP heterozygous individual with subclinical variant Creutzfeldt-Jakob disease. Brain 136, 1139–1145 (2013).
pubmed: 23449776
pmcid: 3613713
doi: 10.1093/brain/awt032
Clarke, P., Will, R. G. & Ghani, A. C. Is there the potential for an epidemic of variant Creutzfeldt-Jakob disease via blood transfusion in the UK? J. R. Soc. Interface 4, 675–684 (2007).
pubmed: 17287181
pmcid: 2373392
doi: 10.1098/rsif.2007.0216
Garske, T. & Ghani, A. C. Uncertainty in the tail of the variant Creutzfeldt-Jakob disease epidemic in the UK. PLoS One 5, e15626 (2010).
pubmed: 21203419
pmcid: 3009744
doi: 10.1371/journal.pone.0015626
Department of Health & Social Care. Risk assessment of the transmission of vCJD by blood components https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/843533/risk-assessment-of-the-transmission-of-vcjd-by-blood-components.pdf (2019).
Bennett, P. & Daraktchiev, M. vCJD and transfusion of blood components: an updated risk assessment. (Department of Health, 2013).
Crowder, L. A., Schonberger, L. B., Dodd, R. Y. & Steele, W. R. Creutzfeldt-Jakob disease lookback study: 21 years of surveillance for transfusion transmission risk. Transfusion 57, 1875–1878 (2017).
pubmed: 28444687
pmcid: 6553617
doi: 10.1111/trf.14145
Holmqvist, J. et al. No evidence of transfusion transmitted sporadic Creutzfeldt-Jakob disease: results from a bi-national cohort study. Transfusion 60, 694–697 (2020).
pubmed: 32187687
doi: 10.1111/trf.15751
Riggs, J. E., Moudgil, S. S. & Hobbs, G. R. Creutzfeldt-Jakob disease and blood transfusions: a meta-analysis of case-control studies. Mil. Med. 166, 1057–1058 (2001).
pubmed: 11778403
doi: 10.1093/milmed/166.12.1057
Wilson, K., Code, C. & Ricketts, M. N. Risk of acquiring Creutzfeldt-Jakob disease from blood transfusions: systematic review of case-control studies. BMJ 321, 17–19 (2000).
pubmed: 10875826
pmcid: 27418
doi: 10.1136/bmj.321.7252.17
Urwin, P. et al. Sporadic Creutzfeldt-Jakob disease in 2 plasma product recipients, United Kingdom. Emerg. Infect. Dis. 23, 893–897 (2017).
pmcid: 5443442
doi: 10.3201/eid2306.161884
UK Government. Advisory committee on the safety of blood, tissues and organs. paediatric components working group - report. importation of plasma and use of apheresis platelets as risk reduction measures for variant Creutzfeldt-Jakob Disease https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/829906/SaBTO_PC_report.pdf (2019).
Concha-Marambio, L. et al. Detection of prions in blood from patients with variant Creutzfeldt-Jakob disease. Sci. Transl. Med. 8, 370ra183 (2016).
pubmed: 28003548
pmcid: 5538786
doi: 10.1126/scitranslmed.aaf6188
Bougard, D. et al. Detection of prions in the plasma of presymptomatic and symptomatic patients with variant Creutzfeldt-Jakob disease. Sci. Transl. Med. 8, 370ra182 (2016).
pubmed: 28003547
doi: 10.1126/scitranslmed.aag1257
Castilla, J., Saá, P., Hetz, C. & Soto, C. In vitro generation of infectious scrapie prions. Cell 121, 195–206 (2005).
pubmed: 15851027
doi: 10.1016/j.cell.2005.02.011
Moudjou, M. et al. Highly infectious prions generated by a single round of microplate-based protein misfolding cyclic amplification. mBio 5, e00829–13 (2013).
pubmed: 24381300
pmcid: 3884057
Cali, I. et al. PMCA-replicated PrP(D) in urine of vCJD patients maintains infectivity and strain characteristics of brain PrP(D): transmission study. Sci. Rep. 9, 5191 (2019).
pubmed: 30914754
pmcid: 6435672
doi: 10.1038/s41598-019-41694-0
Department of Health & Social Care. Transmissible spongiform encephalopathy agents: safe working and the prevention of infection. part 3: laboratory containment and control measures https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/209757/Part_3_-_Laboratory_containment_and_control_measures.pdf (2003).
Honda, H. et al. Abnormal prion protein deposits with high seeding activities in the skeletal muscle, femoral nerve, and scalp of an autopsied case of sporadic Creutzfeldt-Jakob disease. Neuropathology https://doi.org/10.1111/neup.12717 (2021).
doi: 10.1111/neup.12717
pubmed: 34031922
Glatzel, M., Abela, E., Maissen, M. & Aguzzi, A. Extraneural pathologic prion protein in sporadic Creutzfeldt-Jakob disease. N. Engl. J. Med. 349, 1812–1820 (2003).
pubmed: 14602879
doi: 10.1056/NEJMoa030351
Takao, M., Kimura, H., Kitamoto, T. & Mihara, B. PrP
pubmed: 30097055
pmcid: 6086066
doi: 10.1186/s40478-018-0582-5
Head, M. W. et al. Prion protein accumulation in eyes of patients with sporadic and variant Creutzfeldt-Jakob disease. Invest. Ophthalmol. Vis. Sci. 44, 342–346 (2003).
pubmed: 12506094
doi: 10.1167/iovs.01-1273
Kresl, P. et al. Accumulation of prion protein in the vagus nerve in Creutzfeldt-Jakob disease. Ann. Neurol. 85, 782–787 (2019).
pubmed: 30801763
pmcid: 6593447
doi: 10.1002/ana.25451
Orru, C. D. et al. Prion seeding activity and infectivity in skin samples from patients with sporadic Creutzfeldt-Jakob disease. Sci. Transl. Med. 9, eaam7785 (2017).
pubmed: 29167394
pmcid: 5744860
doi: 10.1126/scitranslmed.aam7785
Mammana, A. et al. Detection of prions in skin punch biopsies of Creutzfeldt-Jakob disease patients. Ann. Clin. Transl. Neurol. 7, 559–564 (2020).
pubmed: 32141717
pmcid: 7187701
doi: 10.1002/acn3.51000
Huor, A. et al. Infectivity in bone marrow from sporadic CJD patients. J. Pathol. 243, 273–278 (2017).
pubmed: 28791720
doi: 10.1002/path.4954
Ruegger, J. et al. A case-control study of sporadic Creutzfeldt-Jakob disease in Switzerland: analysis of potential risk factors with regard to an increased CJD incidence in the years 2001-2004. BMC Public Health 9, 18 (2009).
pubmed: 19144172
pmcid: 2637857
doi: 10.1186/1471-2458-9-18
Belondrade, M. et al. Correlation between bioassay and protein misfolding cyclic amplification for variant Creutzfeldt-Jakob disease decontamination studies. mSphere 5, e00649–19 (2020).
pubmed: 31996421
pmcid: 6992370
doi: 10.1128/mSphere.00649-19
Notari, S. et al. Assessing prion infectivity of human urine in sporadic Creutzfeldt-Jakob disease. Emerg. Infect. Dis. 18, 21–28 (2012).
pubmed: 22260924
pmcid: 3310101
doi: 10.3201/eid1801.110589
Moda, F. et al. Prions in the urine of patients with variant Creutzfeldt-Jakob disease. N. Engl. J. Med. 371, 530–539 (2014).
pubmed: 25099577
pmcid: 4162740
doi: 10.1056/NEJMoa1404401
Van Dorsselaer, A. et al. Detection of prion protein in urine-derived injectable fertility products by a targeted proteomic approach. PLoS One 6, e17815 (2011).
pubmed: 21448279
pmcid: 3063168
doi: 10.1371/journal.pone.0017815
Wientjens, D. P. et al. Risk factors for Creutzfeldt-Jakob disease: a reanalysis of case-control studies. Neurology 46, 1287–1291 (1996).
pubmed: 8628468
doi: 10.1212/WNL.46.5.1287
Cocco, P. L., Caperna, A. & Vinci, F. Occupational risk factors for the sporadic form of Creutzfeldt-Jakob disease. Med. Lav. 94, 353–363 (2003).
pubmed: 14526494
Alcalde-Cabero, E. et al. Health professions and risk of sporadic Creutzfeldt-Jakob disease, 1965 to 2010. Euro Surveill. 17, 20144 (2012).
pubmed: 22516047
doi: 10.2807/ese.17.15.20144-en
Hermann, P. et al. Sporadic Creutzfeldt-Jakob disease among physicians, Germany, 1993-2018. Emerg. Infect. Dis. 26, 1710–1719 (2020).
pmcid: 7392457
doi: 10.3201/eid2608.191159
Tenny, S., Kerndt, C. C. & Hoffman, M. R. in StatPearls (StatPearls Publishing LLC., 2021).
Government of Canada. Creutzfeldt-Jakob Disease Surveillance System (CJDSS) Report https://www.canada.ca/en/public-health/services/surveillance/blood-safety-contribution-program/creutzfeldt-jakob-disease/cjd-surveillance-system.html (2021).
Centers for Disease Control and Prevention. Creutzfeldt-Jakob Disease, Classic (CJD). Occurrence and Transmission https://www.cdc.gov/prions/cjd/occurrence-transmission.html (2019).
Nishimura, Y. et al. A nationwide trend analysis in the incidence and mortality of Creutzfeldt–Jakob disease in Japan between 2005 and 2014. Sci. Rep. 10, 15509 (2020).
pubmed: 32968173
pmcid: 7511945
doi: 10.1038/s41598-020-72519-0
Rhoads, D. D. et al. Diagnosis of prion diseases by RT-QuIC results in improved surveillance. Neurology 95, e1017–e1026 (2020).
pubmed: 32571851
doi: 10.1212/WNL.0000000000010086
Murray, K. et al. Is there evidence of vertical transmission of variant Creutzfeldt-Jakob disease? J. Neurol. Neurosurg. Psychiatry 82, 729–731 (2011).
pubmed: 19401289
doi: 10.1136/jnnp.2009.172148
Puopolo, M. et al. Spatial epidemiology of sporadic Creutzfeldt-Jakob disease in Apulia, Italy. Neuroepidemiology 54, 83–90 (2020).
pubmed: 31563913
doi: 10.1159/000503234
Klug, G. M. et al. Enhanced geographically restricted surveillance simulates sporadic Creutzfeldt-Jakob disease cluster. Brain 132, 493–501 (2009).
pubmed: 19042933
doi: 10.1093/brain/awn303
Hannaoui, S., Schatzl, H. M. & Gilch, S. Chronic wasting disease: Emerging prions and their potential risk. PLoS Pathog. 13, e1006619 (2017). Review article summarizing the chronic wasting disease epizootic in deer and elk.
pubmed: 29095921
pmcid: 5667731
doi: 10.1371/journal.ppat.1006619
Osterholm, M. T. et al. Chronic wasting disease in cervids: implications for prion transmission to humans and other animal species. mBio 10, e01091–19 (2019).
pubmed: 31337719
pmcid: 6650550
doi: 10.1128/mBio.01091-19
Våge, J. Chronic Wasting Disease (CWD) identified in a wild reindeer at Hardanger Plateau https://www.vetinst.no/en/news/chronic-wasting-disease-cwd-identified-in-a-wild-reindeer-at-hardanger-plateau (Norwegian Veterinary Institute, 2020).
Mathiason, C. K. et al. Infectious prions in the saliva and blood of deer with chronic wasting disease. Science 314, 133–136 (2006).
pubmed: 17023660
doi: 10.1126/science.1132661
Haley, N. J. et al. Detection of chronic wasting disease prions in salivary, urinary, and intestinal tissues of deer: potential mechanisms of prion shedding and transmission. J. Virol. 85, 6309–6318 (2011).
pubmed: 21525361
pmcid: 3126547
doi: 10.1128/JVI.00425-11
Tamguney, G. et al. Asymptomatic deer excrete infectious prions in faeces. Nature 461, 529–532 (2009).
pubmed: 19741608
pmcid: 3186440
doi: 10.1038/nature08289
Tennant, J. M. et al. Shedding and stability of CWD prion seeding activity in cervid feces. PLoS One 15, e0227094 (2020).
pubmed: 32126066
pmcid: 7053746
doi: 10.1371/journal.pone.0227094
Miller, M. W., Williams, E. S., Hobbs, N. T. & Wolfe, L. L. Environmental sources of prion transmission in mule deer. Emerg. Infect. Dis. 10, 1003–1006 (2004).
pubmed: 15207049
pmcid: 3323154
doi: 10.3201/eid1006.040010
Mathiason, C. K. et al. Infectious prions in pre-clinical deer and transmission of chronic wasting disease solely by environmental exposure. PLoS One 4, e5916 (2009).
pubmed: 19529769
pmcid: 2691594
doi: 10.1371/journal.pone.0005916
Yuan, Q., Telling, G., Bartelt-Hunt, S. L. & Bartz, J. C. Dehydration of prions on environmentally relevant surfaces protects them from inactivation by freezing and thawing. J. Virol. 92, e02191–17 (2018).
pubmed: 29386284
pmcid: 5874414
doi: 10.1128/JVI.02191-17
Angers, R. C. et al. Prions in skeletal muscles of deer with chronic wasting disease. Science 311, 1117 (2006).
pubmed: 16439622
doi: 10.1126/science.1122864
Raymond, G. J. et al. Transmission and adaptation of chronic wasting disease to hamsters and transgenic mice: evidence for strains. J. Virol. 81, 4305–4314 (2007).
pubmed: 17287284
pmcid: 1866158
doi: 10.1128/JVI.02474-06
Di Bari, M. A. et al. Chronic wasting disease in bank voles: characterisation of the shortest incubation time model for prion diseases. PLoS Pathog. 9, e1003219 (2013).
pubmed: 23505374
pmcid: 3591354
doi: 10.1371/journal.ppat.1003219
Perrott, M. R., Sigurdson, C. J., Mason, G. L. & Hoover, E. A. Mucosal transmission and pathogenesis of chronic wasting disease in ferrets. J. Gen. Virol. 94, 432–442 (2013).
pubmed: 23100363
pmcid: 3709615
doi: 10.1099/vir.0.046110-0
Mathiason, C. K. et al. Susceptibility of domestic cats to chronic wasting disease. J. Virol. 87, 1947–1956 (2013).
pubmed: 23236066
pmcid: 3571486
doi: 10.1128/JVI.02592-12
Hamir, A. N. et al. Transmission of chronic wasting disease of mule deer to Suffolk sheep following intracerebral inoculation. J. Vet. Diagn. Invest. 18, 558–565 (2006).
pubmed: 17121083
doi: 10.1177/104063870601800606
Hamir, A. N. et al. Experimental transmission of chronic wasting disease agent from mule deer to cattle by the intracerebral route. J. Vet. Diagn. Invest. 17, 276–281 (2005).
pubmed: 15945388
doi: 10.1177/104063870501700313
Marsh, R. F., Kincaid, A. E., Bessen, R. A. & Bartz, J. C. Interspecies transmission of chronic wasting disease prions to squirrel monkeys (Saimiri sciureus). J. Virol. 79, 13794–13796 (2005).
pubmed: 16227298
pmcid: 1262585
doi: 10.1128/JVI.79.21.13794-13796.2005
Race, B. et al. Lack of transmission of chronic wasting disease to cynomolgus macaques. J. Virol. 92, e00550–18 (2018).
pubmed: 29695429
pmcid: 6026755
doi: 10.1128/JVI.00550-18
Kong, Q. et al. Chronic wasting disease of elk: transmissibility to humans examined by transgenic mouse models. J. Neurosci. 25, 7944–7949 (2005).
pubmed: 16135751
pmcid: 6725448
doi: 10.1523/JNEUROSCI.2467-05.2005
Barria, M. A. et al. Molecular barriers to zoonotic transmission of prions. Emerg. Infect. Dis. 20, 88–97 (2014).
pubmed: 24377702
pmcid: 3884726
doi: 10.3201/eid2001.130858
Kurt, T. D. et al. Human prion protein sequence elements impede cross-species chronic wasting disease transmission. J. Clin. Invest. 125, 2548 (2015).
pubmed: 25961458
pmcid: 4497774
doi: 10.1172/JCI82647
Olszowy, K. M. et al. Six-year follow-up of a point-source exposure to CWD contaminated venison in an upstate New York community: risk behaviours and health outcomes 2005-2011. Public Health 128, 860–868 (2014).
pubmed: 25225155
doi: 10.1016/j.puhe.2014.06.012
Abrams, J. Y., Maddox, R. A., Harvey, A. R., Schonberger, L. B. & Belay, E. D. Travel history, hunting, and venison consumption related to prion disease exposure, 2006-2007 FoodNet Population Survey. J. Am. Diet. Assoc. 111, 858–863 (2011).
pubmed: 21616198
doi: 10.1016/j.jada.2011.03.015
Williams, E. S. Chronic wasting disease. Vet. Pathol. 42, 530–549 (2005).
pubmed: 16145200
doi: 10.1354/vp.42-5-530
Miller, M. W. et al. Epizootiology of chronic wasting disease in free-ranging cervids in Colorado and Wyoming. J. Wildl. Dis. 36, 676–690 (2000).
pubmed: 11085429
doi: 10.7589/0090-3558-36.4.676
Edmunds, D. R. et al. Chronic wasting disease drives population decline of white-tailed deer. PLoS One 11, e0161127 (2016).
pubmed: 27575545
pmcid: 5004924
doi: 10.1371/journal.pone.0161127
Zobeley, E., Flechsig, E., Cozzio, A., Enari, M. & Weissmann, C. Infectivity of scrapie prions bound to a stainless steel surface. Mol. Med. 5, 240–243 (1999).
pubmed: 10448646
pmcid: 2230327
doi: 10.1007/BF03402121
Flechsig, E. et al. Transmission of scrapie by steel-surface-bound prions. Mol. Med. 7, 679–684 (2001).
pubmed: 11713367
pmcid: 1949999
doi: 10.1007/BF03401958
Luhr, K. M., Löw, P., Taraboulos, A., Bergman, T. & Kristensson, K. Prion adsorption to stainless steel is promoted by nickel and molybdenum. J. Gen. Virol. 90, 2821–2828 (2009).
pubmed: 19605588
doi: 10.1099/vir.0.012302-0
Bartz, J. C., Marsh, R. F., McKenzie, D. I. & Aiken, J. M. The host range of chronic wasting disease is altered on passage in ferrets. Virology 251, 297–301 (1998).
pubmed: 9837794
doi: 10.1006/viro.1998.9427
Padilla, D. et al. Sheep and goat BSE propagate more efficiently than cattle BSE in human PrP transgenic mice. PLoS Pathog. 7, e1001319 (2011).
pubmed: 21445238
pmcid: 3060172
doi: 10.1371/journal.ppat.1001319
Espinosa, J. C. et al. Transgenic mice expressing porcine prion protein resistant to classical scrapie but susceptible to sheep bovine spongiform encephalopathy and atypical scrapie. Emerg. Infect. Dis. 15, 1214–1221 (2009).
pubmed: 19751582
pmcid: 2815954
doi: 10.3201/eid1508.081218
Babelhadj, B. et al. Prion disease in dromedary camels, Algeria. Emerg. Infect. Dis. 24, 1029–1036 (2018). First detection of a novel prion disease affecting camels in Algeria, not believed to be related to any known prion diseases.
pubmed: 29652245
pmcid: 6004840
doi: 10.3201/eid2406.172007
World Organization for Animal Health. Camel prion disease: a possible emerging disease in dromedary camel populations? https://oiebulletin.com/wp-content/uploads/2019/12/OIE-News-December-2019-Camel-prion-disease.pdf (2019).
Horigan, V. et al. Assessing the aggregated probability of entry of a novel prion disease agent into the United Kingdom. Microb. Risk Anal. 16, 100134 (2020).
pubmed: 32837979
pmcid: 7428426
doi: 10.1016/j.mran.2020.100134
Food and Agriculture Organization of the United Nations. Data: live animals http://www.fao.org/faostat/en/#data/QA (2020).
Northern Territory Government. Environment: animals. Feral camel https://nt.gov.au/environment/animals/feral-animals/feral-camel (2015).
Jaunmuktane, Z. et al. Evidence for human transmission of amyloid-beta pathology and cerebral amyloid angiopathy. Nature 525, 247–250 (2015). Autopsy study of eight individuals with iCJD demonstrating that amyloid-β may be transmissible via cadaveric hormone injection, analogous to prion protein.
pubmed: 26354483
doi: 10.1038/nature15369
Jaunmuktane, Z. et al. Evidence of amyloid-beta cerebral amyloid angiopathy transmission through neurosurgery. Acta Neuropathol. 135, 671–679 (2018).
pubmed: 29450646
pmcid: 5904220
doi: 10.1007/s00401-018-1822-2
Banerjee, G. et al. Early onset cerebral amyloid angiopathy following childhood exposure to cadaveric dura. Ann. Neurol. 85, 284–290 (2019).
pubmed: 30597599
pmcid: 6492172
doi: 10.1002/ana.25407
Purro, S. A. et al. Transmission of amyloid-beta protein pathology from cadaveric pituitary growth hormone. Nature 564, 415–419 (2018).
pubmed: 30546139
pmcid: 6708408
doi: 10.1038/s41586-018-0790-y
Eisele, Y. S. et al. Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science 330, 980–982 (2010).
pubmed: 20966215
pmcid: 3233904
doi: 10.1126/science.1194516
Olanow, C. W. & Brundin, P. Parkinson’s disease and alpha synuclein: is Parkinson’s disease a prion-like disorder? Mov. Disord. 28, 31–40 (2013).
pubmed: 23390095
doi: 10.1002/mds.25373
Ayers, J. I., Fromholt, S. E., O’Neal, V. M., Diamond, J. H. & Borchelt, D. R. Prion-like propagation of mutant SOD1 misfolding and motor neuron disease spread along neuroanatomical pathways. Acta Neuropathol. 131, 103–114 (2016).
pubmed: 26650262
doi: 10.1007/s00401-015-1514-0
Clavaguera, F. et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc. Natl Acad. Sci. USA 110, 9535–9540 (2013).
pubmed: 23690619
pmcid: 3677441
doi: 10.1073/pnas.1301175110
Hamaguchi, T. et al. Significant association of cadaveric dura mater grafting with subpial Abeta deposition and meningeal amyloid angiopathy. Acta Neuropathol. 132, 313–315 (2016).
pubmed: 27314593
doi: 10.1007/s00401-016-1588-3
Muayqil, T., Gronseth, G. & Camicioli, R. Evidence-based guideline: diagnostic accuracy of CSF 14-3-3 protein in sporadic Creutzfeldt-Jakob disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology 79, 1499–1506 (2012).
pubmed: 22993290
pmcid: 3525296
doi: 10.1212/WNL.0b013e31826d5fc3
National CJD Research & Surveillance Unit. Diagnostic criteria for Creutzfeldt-Jakob disease https://www.cjd.ed.ac.uk/sites/default/files/criteria.pdf (2017).
National CJD Research & Surveillance Unit. Protocol. Surveillance of CJD in the UK https://www.cjd.ed.ac.uk/sites/default/files/NCJDRSU%20surveillance%20protocol-april%202017%20rev2.pdf (2017).
European Centre for Disease Prevention and Control. EU case definition https://www.ecdc.europa.eu/en/infectious-diseases-public-health/variant-creutzfeldt-jakob-disease/eu-case-definition (2017).
McNiven, K. et al. Enteral feeding is associated with longer survival in the advanced stages of prion disease. Brain Commun. 1, fcz012 (2019).
pubmed: 32954259
pmcid: 7425295
doi: 10.1093/braincomms/fcz012
Mead, S. & Rudge, P. CJD mimics and chameleons. Pract. Neurol. 17, 113–121 (2017).
pubmed: 28153848
pmcid: 5520355
doi: 10.1136/practneurol-2016-001571
Otto, M. et al. Efficacy of flupirtine on cognitive function in patients with CJD: a double-blind study. Neurology 62, 714–718 (2004).
pubmed: 15007119
doi: 10.1212/01.WNL.0000113764.35026.EF
Haik, S. et al. Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 13, 150–158 (2014).
pubmed: 24411709
doi: 10.1016/S1474-4422(13)70307-7
Tsuboi, Y., Doh-Ura, K. & Yamada, T. Continuous intraventricular infusion of pentosan polysulfate: clinical trial against prion diseases. Neuropathology 29, 632–636 (2009).
pubmed: 19788637
doi: 10.1111/j.1440-1789.2009.01058.x
Stewart, L. A., Rydzewska, L. H., Keogh, G. F. & Knight, R. S. Systematic review of therapeutic interventions in human prion disease. Neurology 70, 1272–1281 (2008).
pubmed: 18391159
doi: 10.1212/01.wnl.0000308955.25760.c2
Collinge, J. et al. Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurol. 8, 334–344 (2009).
pubmed: 19278902
pmcid: 2660392
doi: 10.1016/S1474-4422(09)70049-3
Geschwind, M. D. et al. Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease. Neurology 81, 2015–2023 (2013).
pubmed: 24122181
pmcid: 4211922
doi: 10.1212/WNL.0b013e3182a9f3b4
Varges, D. et al. Doxycycline in early CJD: a double-blinded randomised phase II and observational study. J. Neurol. Neurosurg. Psychiatry 88, 119–125 (2017).
pubmed: 27807198
doi: 10.1136/jnnp-2016-313541
Barbosa, B. et al. Second-Generation RT-QuIC Assay for the diagnosis of Creutzfeldt-Jakob disease patients in Brazil. Front. Bioeng. Biotechnol. 8, 929 (2020).
pubmed: 32850757
pmcid: 7423993
doi: 10.3389/fbioe.2020.00929
Watson, N. et al. Application of telehealth for comprehensive Creutzfeldt-Jakob disease surveillance in the United Kingdom. J. Neurol. Sci. 420, 117221 (2020).
pubmed: 33223148
doi: 10.1016/j.jns.2020.117221
Appleby, B. S. et al. Feasibility of remote assessment of human prion diseases for research and surveillance. Dement. Geriatr. Cogn. Disord. 47, 79–90 (2019).
pubmed: 30861521
doi: 10.1159/000497055
Klein, B. C. & Busis, N. A. COVID-19 is catalyzing the adoption of teleneurology. Neurology 94, 903–904 (2020).
pubmed: 32238505
doi: 10.1212/WNL.0000000000009494
Abu-Rumeileh, S. et al. Comparison between plasma and cerebrospinal fluid biomarkers for the early diagnosis and association with survival in prion disease. J. Neurol. Neurosurg. Psychiatry 91, 1181–1188 (2020).
pubmed: 32928934
doi: 10.1136/jnnp-2020-323826
Cooper, S. K. et al. Detection of CWD in cervids by RT-QuIC assay of third eyelids. PLoS One 14, e0221654 (2019).
pubmed: 31461493
pmcid: 6713355
doi: 10.1371/journal.pone.0221654
John, T. R., Schatzl, H. M. & Gilch, S. Early detection of chronic wasting disease prions in urine of pre-symptomatic deer by real-time quaking-induced conversion assay. Prion 7, 253–258 (2013).
pubmed: 23764839
pmcid: 3783112
doi: 10.4161/pri.24430
Renard, D., Castelnovo, G., Collombier, L., Thouvenot, E. & Boudousq, V. FDG-PET in Creutzfeldt-Jakob disease: analysis of clinical-PET correlation. Prion 11, 440–453 (2017).
pubmed: 29099286
pmcid: 5786355
doi: 10.1080/19336896.2017.1387348
Vallabh, S. M., Minikel, E. V., Schreiber, S. L. & Lander, E. S. Towards a treatment for genetic prion disease: trials and biomarkers. Lancet Neurol. 19, 361–368 (2020).
pubmed: 32199098
doi: 10.1016/S1474-4422(19)30403-X
National CJD Research and Surveillance Unit. Creutzfeldt–Jakob disease in the UK (by calendar year) https://www.cjd.ed.ac.uk/sites/default/files/figs.pdf (2021).